Begoña Martı́n-Castillo

5.5k total citations
77 papers, 4.0k citations indexed

About

Begoña Martı́n-Castillo is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Begoña Martı́n-Castillo has authored 77 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 39 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Begoña Martı́n-Castillo's work include Metabolism, Diabetes, and Cancer (27 papers), Cancer Cells and Metastasis (16 papers) and HER2/EGFR in Cancer Research (12 papers). Begoña Martı́n-Castillo is often cited by papers focused on Metabolism, Diabetes, and Cancer (27 papers), Cancer Cells and Metastasis (16 papers) and HER2/EGFR in Cancer Research (12 papers). Begoña Martı́n-Castillo collaborates with scholars based in Spain, United States and Australia. Begoña Martı́n-Castillo's co-authors include Javier A. Menéndez, Alejandro Vázquez‐Martín, Cristina Oliveras‐Ferraros, Sílvia Cufí, Jorge Joven, Elisabet Cuyàs, Bruna Corominas-Faja, Joaquim Bosch‐Barrera, Sonia Del Barco and Eugeni López‐Bonet and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Begoña Martı́n-Castillo

76 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Begoña Martı́n-Castillo Spain	39	2.8k	1.7k	1.2k	456	413	77	4.0k
Cristina Oliveras‐Ferraros Spain	39	3.1k 1.1×	1.7k 1.0×	1.1k 1.0×	553 1.2×	602 1.5×	60	4.5k
Sílvia Cufí Spain	37	2.5k 0.9×	1.4k 0.8×	1.1k 0.9×	386 0.8×	444 1.1×	49	3.6k
Victoria Bae‐Jump United States	36	2.1k 0.8×	1.1k 0.6×	1.1k 0.9×	360 0.8×	295 0.7×	212	4.1k
Raymond J. Hohl United States	40	2.3k 0.8×	1.5k 0.9×	818 0.7×	669 1.5×	248 0.6×	138	4.9k
Yanqiao Zhang China	31	1.9k 0.7×	1.8k 1.0×	963 0.8×	1.0k 2.3×	789 1.9×	154	4.3k
Alejandro Vázquez‐Martín Spain	48	4.1k 1.5×	2.1k 1.2×	1.8k 1.5×	689 1.5×	879 2.1×	89	6.1k
Paloma Cejas Spain	27	2.9k 1.1×	1.3k 0.7×	1.3k 1.1×	301 0.7×	214 0.5×	72	4.5k
Khawla S. Al‐Kuraya Saudi Arabia	38	2.4k 0.9×	1.6k 0.9×	1.2k 1.0×	242 0.5×	320 0.8×	163	4.6k
Pixu Liu China	23	3.1k 1.1×	1.2k 0.7×	731 0.6×	271 0.6×	261 0.6×	44	4.4k
Qinhong Xu China	36	1.7k 0.6×	1.2k 0.7×	974 0.8×	354 0.8×	213 0.5×	72	3.2k

Countries citing papers authored by Begoña Martı́n-Castillo

Since Specialization

Citations

This map shows the geographic impact of Begoña Martı́n-Castillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Begoña Martı́n-Castillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Begoña Martı́n-Castillo more than expected).

Fields of papers citing papers by Begoña Martı́n-Castillo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Begoña Martı́n-Castillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Begoña Martı́n-Castillo. The network helps show where Begoña Martı́n-Castillo may publish in the future.

Co-authorship network of co-authors of Begoña Martı́n-Castillo

This figure shows the co-authorship network connecting the top 25 collaborators of Begoña Martı́n-Castillo. A scholar is included among the top collaborators of Begoña Martı́n-Castillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Begoña Martı́n-Castillo. Begoña Martı́n-Castillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martı́n-Castillo, Begoña, et al.. (2025). Metabolic hallmarks of trastuzumab resistance. Expert Opinion on Therapeutic Targets. 29(7). 457–479. 1 indexed citations

Menéndez, Javier A., Ruth Lupu, Begoña Martı́n-Castillo, et al.. (2025). Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy. Frontiers in Immunology. 16. 1695244–1695244.

Verdura, Sara, Eva Martinez‐Balibrea, Joaquim Bosch‐Barrera, et al.. (2025). Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies. Cell Death Discovery. 11(1). 91–91. 3 indexed citations

Vila, E., Sara Verdura, José Antonio Encinar, et al.. (2024). 1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy. Annals of Oncology. 35. S697–S697. 1 indexed citations

Cuyàs, Elisabet, Sara Verdura, Roderic Espín, et al.. (2024). Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity. Cell Death Discovery. 10(1). 417–417. 16 indexed citations

Tramonti, Angela, Elisabet Cuyàs, José Antonio Encinar, et al.. (2021). Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers. 13(16). 4009–4009. 19 indexed citations

Bosch‐Barrera, Joaquim, Ariadna Roqué, M. Carmen Carmona-García, et al.. (2021). Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals. 15(1). 19–19. 4 indexed citations

Cuyàs, Elisabet, Sara Verdura, Begoña Martı́n-Castillo, et al.. (2020). Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers. 12(7). 1757–1757. 19 indexed citations

Cuyàs, Elisabet, Sara Verdura, Laura Llorach-Parés, et al.. (2018). Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell. 17(4). e12772–e12772. 64 indexed citations

10.

Cuyàs, Elisabet, Begoña Martı́n-Castillo, Joaquim Bosch‐Barrera, & Javier A. Menéndez. (2017). Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. Cell Cycle. 16(11). 1022–1028. 20 indexed citations

11.

Martı́n-Castillo, Begoña, Eugeni López‐Bonet, Elisabet Cuyàs, et al.. (2015). Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget. 6(32). 32317–32338. 29 indexed citations

12.

Martı́n-Castillo, Begoña, Eugeni López‐Bonet, María Buxó, et al.. (2015). Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. Oncotarget. 6(9). 7104–7122. 11 indexed citations

13.

Cufí, Sílvia, Alejandro Vázquez‐Martín, Cristina Oliveras‐Ferraros, et al.. (2013). The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Scientific Reports. 3(1). 2469–2469. 104 indexed citations

14.

Cufí, Sílvia, Bruna Corominas-Faja, Alejandro Vázquez‐Martín, et al.. (2012). Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 3(4). 395–398. 120 indexed citations

15.

Cufí, Sílvia, Alejandro Vázquez‐Martín, Cristina Oliveras‐Ferraros, et al.. (2012). Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget. 3(12). 1600–1614. 68 indexed citations

16.

Menéndez, Javier A., Cristina Oliveras‐Ferraros, Sílvia Cufí, et al.. (2012). Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle. 11(15). 2782–2792. 108 indexed citations

17.

Oliveras‐Ferraros, Cristina, Bruna Corominas-Faja, Sílvia Cufí, et al.. (2012). Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle. 11(21). 4020–4032. 113 indexed citations

18.

Oliveras‐Ferraros, Cristina, Alejandro Vázquez‐Martín, Sílvia Cufí, et al.. (2011). Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochemical and Biophysical Research Communications. 407(2). 412–419. 37 indexed citations

19.

Oliveras‐Ferraros, Cristina, Alejandro Vázquez‐Martín, Sílvia Cufí, et al.. (2010). Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells. Journal of Cellular Biochemistry. 112(1). 10–29. 38 indexed citations

20.

Vázquez‐Martín, Alejandro, Cristina Oliveras‐Ferraros, Sonia Del Barco, Begoña Martı́n-Castillo, & Javier A. Menéndez. (2010). The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment. 126(2). 355–364. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact